Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4, Multi-centre, Randomized, Evaluator-blinded, Active-controlled Study to Determine the Incidence of Squamous Cell Carcinoma and Evaluate the Long-term Safety of Tirbanibulin 10 mg/g Ointment and Diclofenac Sodium 3% Gel for the Treatment of Adult Patients With Actinic Keratosis on the Face or Scalp

NCT05387525 is registered in ClinicalTrials.gov with Almirall, S.A. as lead sponsor.

NCT NCT05387525
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05387525 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4, Multi-centre, Randomized, Evaluator-blinded, Active-controlled Study to Determine the Incidence of Squamous Cell Carcinoma and Evaluate the Long-term Safety of Tirbanibulin 10 mg/g Ointment and Diclofenac Sodium 3% Gel for the Treatment of Adult Patients With Actinic Keratosis on the Face or Scalp
Lead sponsor
Almirall, S.A.
Phase
Phase 4
Overall status
Active, not recruiting
Start date
October 24, 2022
Completion date
July 31, 2027
Enrollment
447 (actual)
Sites
49

Conditions

As the registry lists them; a condition with its own page is linked.

keratosis, actinic